AI Score

Unlock

Rockwell Medical Inc. (RMTI)

AI Score

Unlock

1.26

-0.09 (-6.67%)

At close: Mar 24, 2025, 3:59 PM

1.26

0.00%

After-hours: Mar 24, 2025, 07:59 PM EDT

-6.67% (1D)

Bid	1.26
Market Cap	40.88M
Revenue (ttm)	107.74M
Net Income (ttm)	-509.57K
EPS (ttm)	-0.03
PE Ratio (ttm)	-42.17
Forward PE	30
Analyst	Buy

Ask	1.27
Volume	553,379
Avg. Volume (20D)	277,741
Open	1.35
Previous Close	1.35
Day's Range	1.26 - 1.36
52-Week Range	1.26 - 5.15
Beta	1.56

About RMTI

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stor...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 27, 1998

Employees 237

Stock Exchange NASDAQ

Ticker Symbol RMTI

Website https://www.rockwellmed.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 216.21% from the latest price.

Stock Forecasts

Earnings Surprise

Rockwell Medical has released their quartely earnings on Mar 20, 2025:

Revenue of $24.66M exceeds estimates by $2.06M, with 11.64% YoY growth.

EPS of 0.04 exceeds estimates by 0.02, with 100.00% YoY growth.

Why Price Moved

5 days ago

-20.45%

Rockwell Medical shares are trading lower. The com... Unlock content with Pro Subscription

3 months ago

+10.45%

Rockwell Medical shares are trading higher after the company announced expectations for $10 million in FY25 net sales and entered a purchase agreement with a provider of dialysis products and services.

News

4 days ago · seekingalpha.com

Rockwell Medical, Inc. (RMTI) Q4 2024 Earnings Call Transcript

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Heather Hunter - Senior Vice President, Chief Corporate Affairs Officer Mark Strob...

4 days ago · zacks.com

Rockwell Medical (RMTI) Reports Q4 Loss, Tops Revenue Estimates

Rockwell Medical (RMTI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.

5 days ago · businesswire.com

Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history.

2 weeks ago · businesswire.com

Rockwell Medical to Exhibit at DialysisTechConneXion42 in Booth# 112

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion42 on April 1-4, 2025 in Las Vegas, NV in...

3 weeks ago · businesswire.com

Rockwell Medical Named 'Great Place to Work' for Third Year in a Row

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced that it has been certified as a Great Place to Work for the third year in a row.

1 month ago · businesswire.com

Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025.

1 month ago · businesswire.com

Rockwell Medical Adds Single-Use Bicarbonate Cartridge to Hemodialysis Concentrates Product Portfolio

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical adds a 510k approved single-use bicarbonate cartridge--in two sizes, 720g and 900g--to its hemodialysis concentrates po...